

Special Issue

Antifungal Strategies: Epidemiological Approaches, Mechanisms and Resistance in Fungal Pathogens

Message from the Guest Editors

There are several drugs used for the treatment of superficial, subcutaneous, systemic, and opportunistic mycoses. Unfortunately, delay in diagnosis and susceptibility to treatment can result in serious consequences (disability or mortality) for patients, especially for immunocompromised patients, as well as unnecessary costs to health systems. There is evidence of an increase in the resistance of these pathogens to the various antifungal drugs, which differs by region worldwide. More studies of the impact of these diseases in the health sector are needed to better understand the regional characteristics of each one and to facilitate care by obtaining favorable results during empirical treatments. This Special Issue will focus on original and review articles describing antifungal strategies, including the epidemiological and clinical data of mycological infections, in silico studies for molecular targets involved in antifungal resistance, in vitro and in vivo studies focused on molecular/cellular mechanisms associated with Mycoses, studies of natural products, synthetic compounds and repositioning of drugs for the treatment in fungal infections.

Guest Editors

Dr. Erick Martinez-Herrera

Prof. Dr. Rodolfo Pinto-Almazán

Prof. Dr. Carmen Rodríguez-Cerdeira

Deadline for manuscript submissions

31 January 2026



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/221671

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)